Horizon Kinetics Asset Management LLC Raises Position in Alkermes plc (NASDAQ:ALKS)

Horizon Kinetics Asset Management LLC boosted its holdings in Alkermes plc (NASDAQ:ALKSFree Report) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,033 shares of the company’s stock after purchasing an additional 967 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Alkermes were worth $662,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC purchased a new stake in Alkermes during the 4th quarter valued at about $25,000. EverSource Wealth Advisors LLC lifted its position in Alkermes by 106.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock valued at $47,000 after purchasing an additional 842 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Alkermes by 2,231.5% during the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock valued at $49,000 after purchasing an additional 1,629 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Alkermes by 558.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock worth $85,000 after purchasing an additional 2,502 shares during the last quarter. Finally, KBC Group NV increased its stake in shares of Alkermes by 18.8% in the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after buying an additional 774 shares during the period. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ALKS. The Goldman Sachs Group raised their price target on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 14th. HC Wainwright reissued a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft assumed coverage on Alkermes in a research report on Tuesday, February 11th. They set a “buy” rating and a $40.00 price target for the company. UBS Group upgraded Alkermes from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $21.00 to $38.00 in a research report on Tuesday, March 4th. Finally, StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.46.

Get Our Latest Stock Report on ALKS

Insider Activity at Alkermes

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the sale, the executive vice president now directly owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. This represents a 71.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.89% of the stock is owned by corporate insiders.

Alkermes Price Performance

Shares of Alkermes stock opened at $34.37 on Tuesday. Alkermes plc has a 1 year low of $22.90 and a 1 year high of $36.45. The firm has a market cap of $5.59 billion, a price-to-earnings ratio of 15.84, a PEG ratio of 2.20 and a beta of 0.62. The company has a 50-day moving average of $32.50 and a 200 day moving average of $29.90.

Alkermes (NASDAQ:ALKSGet Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. On average, equities analysts anticipate that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Profile

(Free Report)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Further Reading

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKSFree Report).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.